A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2)

Zhong-Hui Jiang†, Xianfeng Shen†, Yanhong Wei, Yongji Chen, Hongbo Chai, Lingyun Xia* and Weidong Leng*

Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, China

Background: Stanniocalcin-2 (STC2) is a secreted glycoprotein which plays an important role in regulating the homeostasis of calcium, glucose homeostasis, and phosphorus metastasis. Accumulating evidence suggests that STC2 is implicated in cancer mechanisms. However, the effects of STC2 on cancer development and progression across pan-cancer are not yet completely known.

Methods: Data were downloaded from The Cancer Genome Atlas database to obtain differentially expressed genes significantly associated with prognosis (key genes). A gene was selected for subsequent correlation studies by integrating the significance of prognosis and the time-dependent ROC curve. Gene expression of different tumor types was analyzed based on the UCSC XENA website. Furthermore, our study investigated the correlation of STC2 expression between prognosis, immune cell infiltration, immune checkpoint genes (ICGs), mismatch repair genes (MMRs), tumor mutation burden (TMB), microsatellite instability (MSI), and drug sensitivity in various malignant tumors. Gene set enrichment analysis (GSEA) was conducted for correlated genes of STC2 to explore potential mechanisms.

Results: A total of 3,429 differentially expressed genes and 397 prognosis-related genes were identified from the TCGA database. Twenty-six key genes were found by crossing the former and the latter, and the highest risk gene, STC2, was selected for subsequent correlation studies. STC2 had good diagnostic performance for HNSCC, and was closely related to the survival status and clinicopathological stage of HNSCC patients. In pan-cancer analysis, STC2 was upregulated in 20 cancers and downregulated in seven cancers. STC2 overexpression was overall negatively correlated with overall survival, disease-free survival, disease-specific survival, and progress-free survival. STC2 was profoundly correlated with the tumor immune microenvironment, including immune cell infiltration, ICGs, MMRs, TMB, and MSI. Moreover, STC2 was significantly negatively correlated with the sensitivity or resistance of multiple drugs.

Conclusion: STC2 was a potential prognostic biomarker for pan-cancer and a new immunotherapy target.

Keywords: stanniocalcin-2, head and neck squamous cell carcinoma, prognostic biomarkers, target therapy, pan-cancer
INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, and the 5-year overall survival rate of HNSCC is only 40–50% by incidence worldwide (Bray et al., 2018). Every year, approximately 600,000 HNSCC cases are diagnosed worldwide (Cohen et al., 2016). HNSCC arises in mucosal epithelium including oral cavity, pharynx, and larynx and is tightly linked to exposure to tobacco-derived carcinogens, alcohol consumption, and human-papillomavirus (HPV) infection (Nakagawa et al., 2021). The prognosis for patients with HNSCC is largely determined by tumor stage at presentation. Early-stage tumors have a favorable prognosis, whereas advanced cancer has poor prognosis. Clinically, most HNSCC patients are diagnosed with advanced cancer with lymph node metastasis. Therefore, this creates an urgent need for practical biomarkers to help in accurate early diagnosis and prediction of tumor prognosis.

Stanniocalcin-2 (STC2) is a secreted glycoprotein which plays a pivotal role in regulating the homeostasis of calcium, glucose homeostasis, and phosphorus metastasis (Takei et al., 2012). STC2 has been shown to play a regulatory role in various tissues and organs in an autocrine or paracrine manner (Chen and Zhu 2008). The correlation between STC2 and tumor progression has been investigated over the last 5 years in multiple studies. STC2 is a useful molecular marker predicting the progression and prognosis of digestive system tumors, including hepatocellular carcinoma (Wang et al., 2019), pancreatic cancer (Lin et al., 2019), gastric cancer (Ke et al., 2019), and colorectal cancer (Zhang et al., 2019). STC2 has also affected extrahepatic cholangiocarcinoma (Li and Yang 2020), nasopharyngeal carcinoma (He et al., 2019), laryngeal cancer (Ding et al., 2021), and osteosarcoma (Yang et al., 2021). STC2 activates ITGB2/FAK/SOX6 and PI3K–AKT signaling pathways in some cancers (Yang et al., 2017; Li et al., 2022). On the other hand, several studies showed that STC2 is a protective factor for some tumors. STC2 reduces resistance to sunitinib in clear-cell renal cell carcinoma (Qin et al., 2022). STC2 inhibits migration and invasion of breast cancer via inhibition of PKC signaling (Hou et al., 1932). Therefore, it is necessary to perform a pan-cancer analysis to reveal the role and underlying molecular mechanisms of STC2 in clinical phenotypic characteristics and tumor immune microenvironments of multiple cancers.

In the present study, we first integrated the samples from the UCSC XENA website to identify the differentially expressed genes (DEGs) and prognosis-related genes. We further screened key genes by crossing the DEGs and prognosis-related genes and selected the highest risk key gene for subsequent pan-cancer analysis. We investigated the correlation between the gene expression and prognosis, immune microenvironment, immune checkpoint genes (ICGs), tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair genes (MMRs), and immune/stromal scores.

MATERIALS AND METHODS

The Datasets

The RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) database and the genotype–tissue expression (GTEx) project were downloaded from the UCSC XENA website (https://xenabrowser.net/datapages/). These data included the 33 different tumor types and matched normal tissues from TCGA and 31 normal human tissues from GTEx. Corresponding clinical profiles were downloaded from these two databases. Duplicated data from these two data sources were excluded. The appropriate gene expression profiles were downloaded from the gene expression omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) to test the results of the TCGA data analysis.

Functional Enrichment Analysis of Upregulated Differentially Expressed Genes

The enrichment of gene ontology (GO) in terms of upregulated DEGs and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was analyzed using the Goplot and ggplot2 package of R. P-value <0.05 was considered significant. GO is a tool widely used for exploring the potential functions of targets, including molecular functions, biological pathways, and cellular components.

Identification of Prognosis-Related Differentially Expressed Genes

The DEGs were identified by “limma” package of R software (version 3.6.3). The results were filtered using adjusted p-value < 0.05 and |log₂(fold change)| > 2 as the threshold to eliminate the potential false-positive results from analysis of TCGA or GTEx. The volcano plot and heat map were plotted using the R package “ggplot2.” In addition, the HNSCC patients were split into a high expression group (HNSCC groups) and a low expression group (HNSCC groups) based on median expression levels of genes. The potential prognostic genes that related to overall survival (OS) in HNSCC were screened using the univariate Cox analysis. The potential prognosis-related DEGs (key genes) were obtained using the R package “VennDiagram.” Time-dependent receiver operating characteristics (ROC) curves for 1, 3, and 5 years were plotted to estimate the predictive power of the key genes. The significance of prognosis and time-dependent ROC curve was further integrated to identify a key gene for follow-up research.

Analysis of the Significance of Stanniocalcin-2 Expression in Prognosis of Head and Neck Squamous Cell Carcinoma and Pan-Cancer

The expression level of STC2 between normal tissue and tumor tissues in HNSCC patients was evaluated. To investigate the diagnostic performance of STC2, the ROC curve was plotted and the area under the curve (AUC) was calculated. An
evaluation of the correlation between STC2 expression level and clinicopathological parameters (e.g., survival status, clinical stage, histologic grade, and T stage) was performed by Pearson’s chi-square test. In addition, we further combined the GTEx database to explore the expression level of STC2 in 33 cancers and corresponding normal tissues to offset the deficiency of a small sample size of normal non-cancerous tissue in TCGA. The Human Protein Atlas (HPA) (https://www.proteinatlas.org/) database was used to illustrate the STC2 protein distribution among normal and cancer tissues. HPA is one of the world’s most frequently visited biological databases. It can provide researchers with high-quality immunohistochemistry images of proteins in the tissue atlas and pathology atlas panels (Dige and Lindskog 2021).

**Survival Analysis**

The association of STC2 with OS, disease-free survival (DFS), disease-specific survival (DSS), and progress-free survival (PFS) was evaluated using Cox regression in various cancer types. According to expression levels of STC2, the HNSCC patients in TCGA were divided into two groups (high and low expression levels) based on the median expression level of STC2 as a cutoff. The analysis process was realized via “survival” and “survminer” packages of R software. The results were visualized using the “forest plot” R package.

**Immunological Correlation Analysis**

To evaluate the association between STC2 expression level and tumor microenvironment (TME) in 33 tumors, the immune scores and stromal scores of each sample were analyzed via the R package “ESTIMATE.” The relationship between STC2 expression and immune checkpoint genes in the TME was examined via the online platform “SangerBox” (http://sangerbox.com/Tool). \( p \)-value < 0.05 was considered statistically significant.
Correlation Analysis of Stanniocalcin-2 With Tumor Mutation Burden, Microsatellite Instability, and Mismatch Repair Genes

TMB, MSI, and MMRs have been proved to be important biomarkers of the TME. The data of five MMRs (EPCAM, PMS2, MLH1, MSH2, and MSH6) and MSI were obtained from the TCGA database. The correlation between STC2 expression levels and MMR gene expression levels, MSI, and TMB was evaluated using the Pearson correlation coefficient. Differences with a p-value < 0.05 were considered to be statistically significant.

Gene Set Enrichment Analysis

GSEA is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states. The samples were divided into two groups (high- and low-expression groups) based on the
STC2 expression levels. KEGG and HALLMARK pathways in the high- and low-expression groups were analyzed using GSEA. The functions involved in both groups were yielded by setting a random combination of 1,000 analyses. A normalized enrichment score (NES) was calculated.

Drug Sensitivity Analysis
To clarify the influence of STC2 expression levels on drug sensitivity and drug tolerance, the processed gene expression and drug sensitivity data were downloaded from the CellMiner database (https://discover.nci.nih.gov/cellminer/). Drugs without FDA approval or clinical trials were removed. The correlation was analyzed using Pearson’s correlation coefficient test, and the cutoff p-value was set to 0.05. The results were visualized using the “limma” and “ggplot2” packages.

Genetic Alteration Analysis
To clarify basic characteristics of STC2, the GeneCards database (https://www.genecards.org/) and COMPARTMENTS (https://compartments.jensenlab.org/Search) database were used to find the genomic location and subcellular location of STC2. The BioPortal web (https://www.ncbi.nlm.nih.gov/) was further utilized to explore the genetic alteration of STC2. All TCGA tumor samples were selected and STC2 mutation rates were queried in different cancers by entering “STC2” in the “TCGA firehose legacy studies.” In addition, a three-dimensional structure diagram of STC2 was obtained.

RESULTS
Differentially Expressed Genes in Head and Neck Squamous Cell Carcinoma
According to the threshold which set adjusted p-value < 0.05 and | log2(fold change)| > 2, a total of 3,429 DEGs (1,861 up-regulated genes and 1568 down-regulated) were identified, as visualized by volcano plots (Figure 1A). To verify the results, an expression profile (GSE30784) of 229 sample data was downloaded from the GEO database. The top 50 most up- and down-regulated genes were plotted in a heat map based on the sample RNA-seq data in GSE30784 (Figure 1B). The results indicated that the screening result of the differential analysis was stable and reliable in the present study. We used GO and KEGG functional enrichment analysis to annotate the function of DEGs (Figure 1C). It was found that the genes significantly upregulated were associated with structural roles for cells.

Prognosis-Related Genes and Their Prognostic Significance for Head and Neck Squamous Cell Carcinoma
A total of 397 prognosis-related genes were identified based on the univariate Cox analysis (p < 0.001). The top 26 genes with the largest significant difference were shown in the forest plot (Figure 2A). The key genes were filtered by crossing the 3,429 DEGs with the
The STC2 expression levels were analyzed in multiple tumors from the TCGA and GTEx databases. The results showed that the expression level of STC2 was significantly different among 27 tumors, except breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), stomach and esophageal carcinoma (STES), bladder urothelial carcinoma (BLCA), acute lymphoblastic leukemia (ALL), and pheochromocytoma and paraganglioma (PCPG) (Figure 3E). Using the HPA database, we found that the expression level of STC2 was significantly increased in HNSC, LGG, LIHC, OV, PAAD, PRAD, STAD, TGCT, THCA, and UCEC. However, STC2 expression was significantly decreased in LUAD and SKCM (Figure 4).

Analysis of Association of Stanniocalcin-2 Expression With Survival in Pan-Cancer

The prognostic significance of STC2 in different cancers was evaluated using Cox regression analyses of the TCGA database. The results showed that high expression levels of STC2 were associated with poorer OS in BLCA, COAD, ESCA, HNSC, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), mesothelioma (MESO), sarcoma (SARC), and thymoma (THYM), but predicted better prognosis in BRCA and brain lower-grade glioma (LGG) (Figure 5A). The correlation analysis of disease-free survival (DFS) found that the STC2 expression level was significantly associated with the prognosis of BRCA, KIRP, LGG, LIHC, and PRAD (Figure 5B). The DSS analysis revealed that high expression of STC2 was significantly associated with poor prognosis in 10 tumors and improved prognosis in two tumors (Figure 5C). According to data on PFS, the high expression of STC2 was significantly associated with prognosis in 12 out of 32 tumors (Figure 5D).

Analysis of the Correlation Between Stanniocalcin-2 and Immunity

To evaluate the role of STC2 in the tumor microenvironment, we analyzed the relationship between STC2 expression level and 60 common ICP gene expressions, including 24 inhibitory and 36 stimulatory. The results showed that correlation between STC2 and ICP genes varied across tumor types (Figure 6A). STC2 expression level was positively correlated with 60 ICP genes in most tumors, including HNSC, BLCA, acute myeloid leukemia (LAML), stomach adenocarcinoma (STAD), and uterine carcinosarcoma (UCS). However, STC2 expression levels were inversely correlated with 60 ICP genes in testicular germ cell tumors (TGCT). It is suggested that STC2 might be involved in the tumor immune microenvironment by coordinating the activity of specific ICP genes. Our study further explored the association of STC2 with immune cell infiltration in 33 tumors. Immune infiltration analysis showed that the expression level of STC2 was associated with the level of immune cell infiltration (including B cell, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) (Figure 6B). Especially in PCPG, kidney chromophobe (KICH), LIHC, there was a strongly positive correlation between the expression level of STC2 and the immune cell infiltration level. In addition, the immune score and stromal score were calculated by the ESTIMATE algorithm (Figure 6C). The results showed that the STC2 expression levels was significantly correlated with immune score in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC).

The Expression of Stanniocalcin-2 in Pan-Cancer

The STC2 expression levels were analyzed in multiple tumors from the TCGA and GTEx databases. The results showed that the expression level of STC2 was significantly different among 27 tumors, except breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), stomach and esophageal carcinoma (STES), bladder urothelial carcinoma (BLCA), acute lymphoblastic leukemia (ALL), and pheochromocytoma and paraganglioma (PCPG) (Figure 3E). Using the HPA database, we found that the expression level of STC2 was significantly increased in HNSC, LGG, LIHC, OV, PAAD, PRAD, STAD, TGCT, THCA, and UCEC. However, STC2 expression was significantly decreased in LUAD and SKCM (Figure 4).
Analyses of Correlation Between Stanniocalcin-2 Expression Levels and Mismatch Repair Genes, Tumor Mutation Burden, and Microsatellite Instability

The results of correlation analysis of STC2 expression level with five MMRs are shown in Figure 7A. The results indicated that expression level of STC2 was significantly correlated with MMRs in almost all cancers except BLCA, cholangiocarcinoma (CHOL), DLBC, glioblastoma multiforme (GBM), KICH, LAML, and SARC. The correlation was most significant in BRCA, CESC, LIHC, LUSC, PRAD, and rectum adenocarcinoma (READ). Our study further investigated the relationship between STC2 expression and TMB. The association between STC2 and TMB was significant in 15 cancer types (Figure 7B). Specifically, the significant and positive correlation between STC2 expression level and TMB was found in HNSC (r = 0.33, p < 0.001), PCPG (r = 0.38, p < 0.001), thyroid carcinoma (THCA) (r = 0.32, p < 0.001), TGCT (r = 0.47, p < 0.001), and UVM (r = 0.33, p = 0.0028).
and THCA \((r = -0.12, p < 0.01)\). In another five types of adrenocortical carcinoma (ACC), BRCA, HNSC, LUSC, and TGCT, STC2 expression was related to MSI (Figure 7C). The results demonstrated that upregulated STC2 expression was significantly associated with increased TMB in ACC \((r = 0.22, p < 0.05)\), HNSC \((r = 0.12, p < 0.01)\), LUSC \((r = 0.17, p < 0.001)\), and TGCT \((r = 0.19, p < 0.05)\), while it was associated with decreased TMB in BRCA \((r = 0.11, p < 0.001)\).
Potential Functions of the Stanniocalcin-2–Correlated Genes

The GSEA enrichment analysis revealed that STC2 was the focus of many signaling pathways associated with cancer. The KEGG pathway enrichment analysis of upregulated STC2 revealed a significant enrichment of linoleic acid metabolism, olfactory transduction, RIG-I–like receptor signaling pathway, and intestinal immune network for IgA production (Figures 8A–D). The HALLMARK pathway analysis revealed that allograft rejection, epithelial–mesenchymal, interferon α response, and interferon γ response were enriched in high STC2 (Figures 8E–H).

Drug Sensitivity Analysis

We analyzed the correlation between STC2 expression and drug sensitivity based on the CellMiner database. The top 16 drugs with the strongest correlations were shown in Figure 9. The results suggested that upregulation of STC2 expression reduced the sensitivity to a number of drugs, including PF-4942847, MPC-3100, SNX-5422, TAK-632, TAS-116, BGB-283, geldanamycin analog, alvespimycin, AT-13387, dabrafenib, XL-888, tanespimycin, ganetespib, CUDC-305, ARQ-680, and SB-590885.

Basic Biology of Stanniocalcin-2 and Genetic Alteration Analysis

STC2 is a protein-coding RNA located at q35.2 in Chromosome 5 (Figure 10A). The subcellular location of STC2 was found using COMPARTMENTS. The highest confidence in the subcellular location was in the endoplasmic reticulum and perinuclear region of the cytoplasm (Figure 10B). The cBioportal was used to explore the genetic alteration of STC2. The results revealed 200 mutations of STC2 in 8,681 patients with different tumors. Among them, renal cell carcinoma patients had the highest frequency of STC2 gene alteration (15.82%) and the most alterations were amplification (15.44%, 82/531). The mutation frequency of adrenocortical carcinoma is the highest at about 2.17% (Figure 10C). We present the three-dimensional (3D) structure of the STC2 protein in Figure 10D.

DISCUSSION

STC2 as a glycoprotein is expressed in the broad-spectrum of human tumor cells and tissues, including breast, bone, esophagus, liver, lung, kidney, ovary, prostate, and stomach (Qie and Sang 2022). Under stress conditions such as hypoxia (Law et al., 2008; Law and Wong 2010), ER stress (Joshi et al., 2015), and nutrient deprivation (He et al., 2019), both transcriptional and post-transcription of STC2 were regulated, and in turn drives tumor cell growth, proliferation, and tumorigenesis. Moreover, STC2 is identified as an immune response–related gene and upregulated in T-cells with Th2 response (Jansen et al., 2015; Roche et al., 2018). Importantly, STC2 mediates resistance to chemo- and radio-therapies and promotes the development of tumor cell–acquired resistance (Garnett et al., 2004). Hence, we investigated the correlations of STC2 expression level with...
prognosis, immune checkpoint, MMRs, TMB, MSI, function notation, and related pathways in 33 distinct tumors based on the data from TCGA and GTEx.

First, we assessed the mRNA expression levels of STC2 in tumors. The results revealed that the expression level of STC2 was significantly up-regulated in most cancers. Furthermore, we investigated the clinical prognostic value of STC2 expression levels in tumors by univariate Cox regression. In line with previous reports, high expression of STC2 suggested an unfavorable prognosis in BLCA, COAD, ESCA, HNSC, KIRP, LIHC, LUAD, MESO, SARC, and THYM. In the progression of COAD, STC2 contributed to cancer cell metastasis by promoting epithelial–mesenchymal transition (Chen et al., 2016). Moreover, STC2 also plays a critical role in the progression of HNSCC. STC2 enhanced PI3K/Akt signaling pathways by upregulation of Snail-mediated decrease of E-cadherin, and promoted HNSCC metastasis (Yang et al., 2017). The overexpression of STC2 leads to poor prognosis in LIHC. STC2 could regulate drug efflux and drug resistance of tumor cells by regulating the expression levels of P-glycoprotein and Bcl-2 protein (Shi et al., 2020). In contrast, favorable prognostic indications were found in BRCA and LGG.

As integral components of the tumor immune microenvironment, tumor-infiltrating immune cells (TIICs) were biomarkers for prognosis and response to immunotherapy in various carcinomas (Zhang and Zhang 2020). Many markers including immune checkpoints, TMB,
and MSI have been used to evaluate immunotherapy susceptibility (Vrána et al., 2018; Li et al., 2020). Therefore, we investigated the relationship between STC2 expression level and TIICs, immune scores, and stromal scores in multiple malignancies. We observed a significant positive correlation between STC2 expression level and infiltration levels of B cells, CD4+ T cells, CD8+ T cells, neutrophil, macrophage, and dendritic cells in PRAD, LIHC, KICH, and KIRC. STC2 was an interaction partner of histidine-rich glycoprotein (HRG) located on the surface of inflammatory cells. HRG was a cation- and heparin-binding, 75 kDa plasma glycoprotein produced by liver hepatocytes (Poon et al., 2011), which could generate antitumor immune responses by controlling the phenotypic switch of macrophages. STC2 could form a histidine-rich glycoprotein/stanniocalcin-2 (HRG/STC2) complex with HRG to regulate murine glioma growth via modulation of anti-tumor immunity (Roche et al., 2018). Moreover, the previous animal model study showed that STC2 knockdown in murine mesenchymal stem cells significantly impairs its effect in reducing TNF-α- and IFN-γ-producing CD8+ T cells (Chen et al., 2018). It is well known that T cells recognize tumor antigens and delivering them to T-cell receptors is a major process in tumor immune regulation (Grinberg-Bleyer et al., 2017). When T-cell function is impaired,
cancer cells can evade immune surveillance by multiple mechanisms. Among them, cancer cells exploit various intrinsic immune checkpoints of T cells to escape from immune surveillance; thus, they are important pathways for escaping (Tan et al., 2017). The immune checkpoints are regulators of the immune system and can attenuate T-cell responses to maintain immune homeostasis and prevent autoimmunity (Liu et al., 2020). However, tumors can use various mechanisms to hijack these pathways to evade immune recognition against tumor antigen-specific T cells (Cohen et al., 2016). Therefore, the expression levels of immune checkpoint genes and their ligands are often up-regulated in the tumor immune microenvironment (Zhao et al., 2018). A significant positive correlation between the expression level of STC2 and the expression levels of immune checkpoint genes was observed in most cancers in our study. These findings suggested that STC2 may play an important role in tumor immune avoidance mechanisms. However, the in vivo biological importance of STC2 remains to be further dissected, which will be a target for our future study.

MMRs are key players in a post-replication repair system and are involved in repairing DNA base mismatches and indels during the S phase. As a safety and security system, MMRs play a crucial role in ensuring the stability of DNA replication and avoiding the generation of genetic mutations. Mutations or defects in the MMR genes could contribute to the accumulation
of genetic errors, resulting in the occurrence of tumors (Geisler et al., 2003). Therefore, we assessed in detail the association of five MMRs (MLH1, MSH2, MSH6, PMS2, and EPCAM) with STC2 expression levels in 33 cancers. The results of Pearson analysis confirmed that STC2 expression level was significantly and positively correlated with DNA repair genes in most types of cancer. MSI is another marker of genomic instability and is a hallmark of MMR defects (Law and Wong 2010). MSI is closely linked to the occurrence, development, and prognosis of various cancers. A study by Gryfe et al. (2000) shows that high-frequency MSI is an independent predictor of clinical characteristics and prognosis in COAD. Compared with low levels of MSI, high levels of MSI exhibit a better anti-tumor immune response, the ability to inhibit tumor cell growth, improved prognosis, and microsatellite stability (Kim et al., 2016; Marrelli et al., 2016; Mohan et al., 2016). TMB might influence the utility of immunotherapy by affecting the generation of immunogenic peptides. Previous studies have revealed that TMB improves the efficacy of immunotherapy in colorectal cancer (Lee et al., 2019) and non-small cell lung cancer (Devarakonda et al., 2018). Therefore, we investigated the correlation between STC2 expression levels with TMB and MSI in 33 tumors. An important finding was that STC2 expression was significantly associated with TMB in 15 cancers and MSI in five cancers. The results suggest that STC2 might serve as a promising tumor therapeutic target to improve the immunotherapy response.

The lack of tumor specificity and drug resistance remains a significant barrier to effective cancer therapy and might be associated with tumor recurrence. Previous studies indicate that STC2 is upregulated upon exposure to several chemotherapeutic treatments. Miyazaki et al. (2014) found that STC2 was the most highly upregulated gene in anti-VEGF antibody–treated colon cancer. This indicated that STC2 might contribute to the development of acquired drug resistance to anti-VEGF treatment. Wang et al. (2015) found that STC2 could promote cell proliferation and cisplatin resistance in cervical cancer by regulating the activity of the MAPK signaling pathway. STC2 promoted activation of the PI3K–Akt signaling pathway and induced the expression of P-glycoprotein which also increases the drug resistance of tumor cells (Yuan et al., 2016). P-glycoprotein was an efflux pump involved in the absorption, distribution, and excretion of chemical compounds and implicated in the poor penetration of many drugs (Brown et al., 2018). The drug sensitivity analysis based on the CellMiner database found that STC2 expression levels are significantly associated with some drug sensitivity, such as PF-4942847, MPC-3100, SNX-5422, TAK-632, TAS-116, BGB-283, geldanamycin analog, and alvespimycin. It is likely that STC2 upregulated might play an important role in drug resistance.

Genetic alteration is a main factor that drives cancer, including altering genetic content, disrupting genes, and causing phenotypic differences. Cancer genomes typically develop four to five driver mutations when combining coding and noncoding genomic elements, and their instability is a molecular genetic hallmark of tumorigenesis (Bray et al., 2018). Gene amplification is a major manifestation of genomic instability and plays a crucial role in various cancers. In recent years, growing evidence has indicated that mutated-gene–targeted therapy is a promising strategy for tumors (Synnott et al., 2017; Kaur et al., 2018). Our study found that STC2 is mutated in most cancers, and the frequency of STC2 gene mutation in renal cell carcinoma patients reached 15.2%; most of the alterations were amplification. This result further demonstrates that STC2 is a plausible therapeutic target.

To our knowledge, this study is the first comprehensive pan-cancer analysis of STC2. This study systematically investigated pan-cancer information from multiple databases. However, there are still inevitable limitations in our study. First, we did not find that STC2 was differentially expressed between some tumor tissue (BLCA, BRCA, and ESCA) and normal tissue in the previous results of analysis of differentially expressed genes. Therefore, the diagnostic and prognostic value of STC2 in BLCA, BRCA, and ESCA should be further validated with a large number of cases. Second, as our study is limited to the analysis of the existing data, more experimental studies are needed to validate these bioinformatics results. Further research will contribute to clarifying the role of STC2 at the molecular level. Third, although pan-cancer analysis results support that STC2 expression was associated with immunomodulatory mechanisms and immune cell infiltration, the underlying mechanism remains to be further investigated.

CONCLUSION

In conclusion, we analyzed data in public databases and found the abnormal expression of STC2 is significantly correlated with the prognosis of HNSCC and can be used as a biomarker for the prognosis of HNSCC. In pan-cancer analysis, STC2 is significantly associated with prognosis, immune cell infiltration, immune checkpoints, immune scoring, mechanistic scoring, TMB, MSI, and MMRs in multiple cancers. This provides a certain basis for bioinformatics analysis for future studies of STC2 in tumor immunity and tumor microenvironment. However, the aforementioned results still require further biological experiments to verify the function and molecular mechanism.

AUTHOR CONTRIBUTIONS

Study conception and design: Z-HJ and WL. Data collection: Z-HJ, XS, and YW. Statistical analysis: LX and XS. Manuscript draft: Z-HJ and YC. Manuscript review and editing: LX, HC, and WL.

FUNDING

Innovative Research Program for Graduates of the Hubei University of Medicine (No. YC2021046). Scientific research projects of Shiyan Science and Technology department (No. 2021K68).
ACKNOWLEDGMENTS

We thank the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) for providing the data for this study.

REFERENCES

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 68 (6), 394–424. doi:10.3332/ca.214192
Brown, N. F., Williams, M., Arkenau, H.-T., Fleming, R. A., Tolson, J., Yan, L., et al. (2018). A Study of the Focal Adhesion Kinase Inhibitor GSK2265098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C] GSK2265098. Neuro Oncol. 20 (12), 1634–1642. doi:10.1093/neuonc/noy078
Chen, B., Zeng, X., He, Y., Wang, X., Liang, Z., Liu, J., et al. (2016). STC2 Promotes the Epithelial-Mesenchymal Transition of Colorectal Cancer Cells through AKT-ERK Signaling Pathways. Oncotarget 7 (44), 71400–71416. doi:10.18632/oncotarget.12147
Chen, W. N., and Zhu, G. J. (2008). Progress in the Research of Stanniocalcin. Sheng Li Ke Xue Jin Zhan 39 (3), 225–228.
Chen, X., Liu, Q., Huang, W., Cai, C., Xia, W., Peng, Y., et al. (2018). Stanniocalcin-2 Contributes to Mesenchymal Stromal Cells Attenuating Murine Cutaneous Hypersensitivity Mainly via Reducing CD8+ Tc1 Cells. Cell. Death Dis. 9 (5), 548. doi:10.1038/s41419-018-0164-x
Cohen, E. E. W., LaMonte, S. J., Erb, N. L., Beckman, K. L., Sadeghi, N., Hutcheson, A. M., et al. (2019). STC2 Hallmarks ER-Positive Inflammatory Breast Cancer and Endocrine Therapy Resistance in Advanced Disease. Mol. Oncol. 9 (6), 1218–1233. doi:10.1002/molonc.2015.02.006
Joshlin, A. D., Carter, D. E., Harper, T. A., Jr., and Elferink, C. J. (2015). Aryl Hydrocarbon Receptor-dependent Stanniocalcin 2 Induction by Cinnabaric Acid Provides Cytoprotection against Endoplasmic Reticulum and Oxidative Stress. J. Pharmacol. Exp. Ther. 353 (1), 201–212. doi:10.1124/jpet.114.222265
Kaur, R. P., Vasudeva, K., Kumar, R., and Munshi, A. (2018). Role of P53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies. Cpd 24 (30), 3566–3575. doi:10.2174/18161282466180926097590
Ke, J., Zhang, B. H., Li, Y.-Y., Zhong, M., Ma, W., Xue, H., et al. (2019). MiR-1–3p Suppresses Cell Proliferation and Invasion and Targets STC2 in Gastric Cancer. Eur. Rev. Med. Pharmacol. Sci. 23, 8870–8877. doi:10.26355/eurrev_201910_19282
Kim, C. G., Ahn, J. B., Jung, M., Beom, S. H., Kim, C., Kim, J. H., et al. (2016). Effects of Microsatellite Instability on Recurrence Patterns and Outcomes in Colorectal Cancers. Br. J. Cancer 115, 25–33. doi:10.1038/bjc.2016.161
Law, A. Y. S., Li, K. P., Ip, C. K. M., Wong, A. S. T., Wagner, G. F., and Wong, C. K. C. (2008). Epigenetic and HIF-1 Regulation of STNNE-2 Expression in Human Cancer Cells. Exp. Cell. Res. 314 (8), 1823–1830. doi:10.1016/j.yexcr.2010.06.003
Law, A. Y. S., and Wong, C. K. C. (2010). STNNE-2 Is a HIF-1 Target Gene that Promotes Cell Proliferation in Hypoxia. Exp. Cell. Res. 316 (3), 466–476. doi:10.1016/j.yexcr.2009.09.018
Lee, D.-W., Han, S.-W., Bae, J. M., Jiang, H., Han, H., Kim, H., et al. (2019). Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Clin. Cancer Res. 25, 6141–6147. doi:10.1158/1078-0432.CCR-19-1105
Li, J., Yang, Z., Huang, S., and Li, D. (2020). BIRC7 and STC2 Expression Are Associated with Tumorigenesis and Poor Outcome in Extrahaepatic Cholangiocarcinoma. Technol. Cancer Res. Treat. 19, 153303382097167.
Li, J., Zhang, Z., Feng, X., Shen, Z., Sun, J., Zhang, X., et al. (2022). Stanniocalcin-2 Promotes Cell EMT and Glycolysis via Activating ITGB2/PAX36 Signaling Pathway in Nasopharyngeal Carcinoma. Cell. Biol. Toxicol. 1573–6822. doi:10.1007/s10565-021-09600-5
Li, L., Feng, Q., and Wang, X. (2020). PreMSim: An R Package for Predicting Microsatellite Instability from the Expression Profiling of a Gene Panel in Cancer. Comput. Struct. Biotechnol. J. 18, 668–675. doi:10.1016/j.csbj.2020.03.007
Lin, C. A.-O., Sun, L. A.-O., Huang, S. A.-O., and Wu, Z. A.-O. (2019). STC2 Is A Potential Prognostic Biomarker for Pancreatic Cancer and Promotes Migration and Invasion by Inducing Epithelial-Mesenchymal Transition. Biomed. Res. Int., 2314–6114. doi:10.1155/2019/8042489
Liu, Y., Zuzagaitis, I., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., et al. (2020). Immune Cell PD-L1 Co-localizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clin. Cancer Res. 26 (4), 970–977. doi:10.1158/1078-0432.CCR-19-1040
Marrelli, D., Polom, K., Pascale, V., Vindigni, C., Piagnerelli, R., De Franco, L., et al. (2016). Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann. Surg. Oncol. 1534–4681. doi:10.1245/s10434-015-4931-3
Miyazaki, S., Kikuchi, H., Iino, I., Uehara, T., Setoguchi, T., Fujita, T., et al. (2014). STC2 Hallmarks ER-Positive Inflammatory Breast Cancer and Endocrine Therapy Resistance in Advanced Disease. Mol. Oncol. 9 (6), 1218–1233. doi:10.1002/mono.2015.02.006
Mohamed, H. M., Ryan, E., Balasubramanian, I., Kennedy, R., Geraghty, R., Sclafani, F., et al. (2016). Microsatellite Instability Is Associated with Reduced Disease Specific Survival in Stage III Colon Cancer. Eur. J. Surg. Oncol. 1532–2157. doi:10.1016/j.ejso.2016.05.013

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgen.2022.927046/full#supplementary-material
Nakagawa, T., Kurokawa, T., Mima, M., Imamoto, S., Mizokami, H., Kondo, S., et al. (2021). DNA Methylation and HPV-Associated Head and Neck Cancer. Microorganisms 9 (4). doi:10.3390/microorganisms9040801

Poon, I. K., Patel, K. K., Davis, D. S., Parish, C. B., and Hulett, M. D. (2011). Histidine-rich Glycoprotein: the Swiss Army Knife of Mammalian Plasma. Blood 117 (7), 2093–2101. doi:10.1182/blood-2010-09-303842

Qie, S., and Sang, N. (2022). Stanniocalcin 2 (STC2): a Universal Tumour Biomarker and a Potential Therapeutical Target. J. Exp. Clin. Cancer Res. 41 (1), 161. doi:10.1186/s13046-022-02370-w

Qin, Z. Q., Li, K. D., Chu, H. Z., Yuan, X. F., Shi, H. F., Gu, J., et al. (2022). Blocking Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity. Mol. Cancer Ther. 17 (9), 1961–1972. doi:10.1158/1535-7163.MCT-18-0097

Shi, W., Feng, L., Dong, S., Ning, Z., Hua, Y., Liu, L., et al. (2020). Exploration of Prognostic Index Based on Immune-Related Genes in Patients with Liver Hepatocellular Carcinoma. Biosci. Rep. 40 (7). doi:10.1042/BSR20194240

Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., et al. (2017). Mutant P53: a Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer? Int. J. Cancer 140 (1), 234–246. doi:10.1002/ijc.30425

Takei, Y., Yamamoto, H., Sato, T., Otani, A., Kozai, M., Masuda, M., et al. (2012). Stanniocalcin 2 Is Associated with Ectopic Calcification in α-klotho Mutant Mice and Inhibits Hyperphosphatemia-Induced Calcification in Aortic Vascular Smooth Muscle Cells. Bone 50 (4), 998–1005. doi:10.1016/j.bone.2012.01.006

Tan, P., He, L., Han, G., and Zhou, Y. (2017). Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends Biotechnol. 35 (3), 215–226. doi:10.1016/j.tibtech.2016.09.002

Vrâna, D., Matzenauer, M., Neoral, Č., Ajueský, R., Vrba, R., Melichar, B., et al. (2018). From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. Int. J. Mol. Sci. 20 (1), doi:10.3390/ijms20010013

Wang, Y., Gao, Y., Cheng, H., Yang, G., and Tan, W. (2015). Stanniocalcin 2 Promotes Cell Proliferation and Cisplatin Resistance in Cervical Cancer. Biochem. Biophys. Res. Commun. 466 (3), 362–368. doi:10.1016/j.bbrc.2015.09.029

Wang, Y., Wu, J., Xu, J., and Lin, S. (2019). Clinical Significance of High Expression of Stanniocalcin-2 in Hepatocellular Carcinoma. Biosci. Rep. 39 (4). doi:10.1042/BSR20182057

Yang, M., Ma, X., Wang, Z., Zhang, T., Hua, Y., and Cai, Z. (2021). Identification of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis of Osteosarcoma Patients. Aging (Albany NY) 13, 12896–12918. doi:10.18632/aging.202958

Yang, S., Ji, Q., Chang, B., Wang, Y., Zhu, Y., Li, D., et al. (2017). STC2 Promotes Head and Neck Squamous Cell Carcinoma Metastasis through Modulating the PI3K/AKT/Snail Signaling. Oncotarget 8 (4), 5976–5991. doi:10.18632/oncotarget.13355

Yuan, Q., Zhan, L., Zhang, L. L., Wang, Q., Liu, J., Jiang, Z. Y., et al. (2016). Stanniocalcin 2 Induces Oxaliplatin Resistance in Colorectal Cancer Cells by Upregulating P-Glycoprotein. Can. J. Physiol. Pharmacol. 94 (9), 929–935. doi:10.1139/cjpp-2015-0530

Zhang, C., Chen, S., Ma, X., Yang, Q., Su, F., Shu, X., et al. (2019). Upregulation of STC2 in Colorectal Cancer and its Clinicopathological Significance. Oncotarget 12, 1249–1258. doi:10.2147/OTT.S191609

Zhang, Y., and Zhang, Z. (2020). The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications. Cell. Mol. Immunol. 17 (8), 807–821. doi:10.1038/s41423-020-0488-6

Zhao, Y., Shuen, T. W. H., Toh, T. B., Chan, X. Y., Liu, M., Tan, S. Y., et al. (2018). Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-specific Tumour Microenvironment and Immunotherapy. Gut 67 (10), 1845–1854. doi:10.1136/gutjnl-2017-315201

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jiang, Shen, Wei, Chen, Chai, Xia and Leng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

HNSCC  Head and neck squamous cell carcinoma
HPV   Human-papillomavirus
STC2  Stanniocalcin-2
DEGs  Differentially expressed genes
ICG   Immune checkpoint gene
TMB   Tumor mutation burden
MSI   Microsatellite instability
MMRs  Mismatch repair genes
TCGA  The Cancer Genome Atlas
GTeX  Genotype-tissue expression
KEGG  Kyoto Encyclopedia of Genes and Genomes
GO    Gene Ontology
ROC   Receiver operating characteristics
AUC   Area under the curve
HPA   Human Protein Atlas
OS    Overall survival
DFS   Disease-free survival
DSS   Disease-specific survival
PFS   Progress-free survival
HRG   Histidine-rich glycoprotein
HRG/STC2  Histidine-rich glycoprotein/stanniocalcin-2
ACC   Adrenocortical carcinoma
BLCA  Bladder urothelial carcinoma
BRCA  Breast invasive carcinoma
CESC  Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL  Cholangiocarcinoma
COAD  Colon adenocarcinoma
DLBC  Lymphoid neoplasm diffuse large B-cell lymphoma
ESCA  Esophageal carcinoma
GBM   Glioblastoma multiforme
HNSC  Head and neck squamous cell carcinoma
KICH  Kidney chromophobe
KIRC  Kidney renal clear cell carcinoma
KIRP  Kidney renal papillary cell carcinoma
LAML  Acute myeloid leukemia
LGG   Brain lower grade glioma
LIHC  Liver hepatocellular carcinoma
LUAD  Lung adenocarcinoma
LUSC  Lung squamous cell carcinoma
MESO  Mesothelioma
OV    Ovarian serous cystadenocarcinoma
PAAD  Pancreatic adenocarcinoma
PCPG  Pheochromocytoma and paraganglioma
PRAD  Prostate adenocarcinoma
READ  Rectum adenocarcinoma
SARC  Sarcoma
SKCM  Skin cutaneous melanoma
STAD  Stomach adenocarcinoma
TGCT  Testicular germ cell tumors
THCA  Thyroid carcinoma
THYM  Thymoma
UCEC  Uterine corpus endometrial carcinoma
UCS   Uterine carcinosarcoma
UVM   Uveal melanoma